Lantheus Q2 2024 Earnings Report
Key Takeaways
Lantheus reported a strong second quarter with worldwide revenue of $394.1 million, a 22.5% increase from Q2 2023. Growth was primarily driven by PYLARIFY and DEFINITY. The company completed three strategic transactions to expand its radiopharmaceutical pipeline. GAAP fully diluted earnings per share were $0.88, while adjusted fully diluted earnings per share were $1.80.
Worldwide revenue increased 22.5% to $394.1 million compared to the same period in 2023, driven by PYLARIFY and DEFINITY.
PYLARIFY sales were $273.3 million, a 29.8% increase year-over-year, driven by increased utilization and market expansion.
DEFINITY sales were $78.1 million, a 10.7% increase year-over-year.
Net cash provided by operating activities and free cash flow were $84.7 million and $73.5 million, respectively.
Lantheus
Lantheus
Lantheus Revenue by Segment
Forward Guidance
The Company maintains full year 2024 revenue guidance and updates fully diluted earnings per share guidance driven by strategic transactions
Positive Outlook
- FY 2024 Revenue: $1.50 billion - $1.52 billion
Challenges Ahead
- FY 2024 Adjusted Fully Diluted EPS: $6.60 - $6.70